HER2/neu-specific antibodies and methods of using same
AssigneeMacroGenics, Inc.
InventorsLeslie S. Johnson, Ling Huang, Nadine Tuaillon, Ezio Bonvini
Life of this patent
Estimating the term…
Abstract
This invention relates to antibodies that specifically bind HER2/neu, and particularly chimeric 4D5 antibodies to HER2/neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
Claims38
A method of treating a HER2/neu-expressing cancer in a patient in need thereof having a CD16A Fc Receptor comprising a Phe at position 158, comprising administering to said patient a therapeutically effective amount of an antibody that binds human HER2/neu and comprises:
- (A) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO:
- 2;
- and
- (B) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO:
- 9, SEQ ID NO:
- 11, or SEQ ID NO:
- 13.
A method of treating a HER2/neu-expressing cancer in a patient in need thereof having a CD16A Fc Receptor comprising a Phe at position 158, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising an antibody that binds human HER2/neu and comprises:
- (A) an immunoglobulin light chain comprising an amino acid sequence of SEQ ID NO:
- 2;
- and
- (B) an immunoglobulin heavy chain comprising an amino acid sequence of SEQ ID NO:
- 9, SEQ ID NO:
- 11, or SEQ ID NO:
- 13;
- and
- (C) a pharmaceutically acceptable carrier and/or an excipient.
Dependencies are inferred from the claim text.